Frontlight ResearchEarly access
CompletedNo phase
CES for the Treatment of GAD in Young Adults
Key facts
- Who runs it
- Electromedical Products International, Inc.
- Where
- Chapel Hill, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 130 people enrolled
- Started
- 26 Jan 2024
- Ended
- 21 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- At-Home Stimulation
- Record updated
- 18 March 2026
Who can take part
- Age
- 18 years to 21 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Capable of signing informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study including refraining from changes to treatment unless medically indicated and communicated to the study team
- Aged 18 - 21 at time of screening visit
- Diagnosis of generalized anxiety disorder (GAD)
- At least mild-to-moderate symptom severity, as indicated by scores of 15 or higher on the clinician-administered HAM-A at the screening visit
- Concurrent psychiatric medications are allowed. Participants will be required to maintain a sable dose of medications, or remain medication free, for 2 weeks prior to the screening visit, except for antidepressants for which the period of stable dose is 4 weeks prior to screening visit. Concurrent psychotherapy is allowed
- People of reproductive potential must be willing to use effective contraception (evidence-based hormonal or barrier methods) for at least 1 month prior to the screening visit and agree to use such a method during study participation
Who cannot take part
- Current (any) or previous (> 7 stimulation sessions in last 6 weeks) use of a CES device
- Experimental or clinical brain stimulation such as deep brain stimulation or transcranial magnetic stimulation for any indication (current or within 60 days prior to screening visit)
- Diagnosis (based on MINI) of bipolar I or II (past or current), moderate or severe alcohol use disorder (within 12 months prior to screening visit), moderate or severe (non-alcohol) substance use disorder (within 12 months prior to screening visit), psychotic disorder (current or lifetime), major depressive disorder with psychotic features, bipolar I with psychotic features, anorexia nervosa
- Enrollment in clinical trial for any condition (current or within 60 days prior to screening visit)
- Self-harming behaviors (current or within two years prior to screening visit)
- Epilepsy (current or history). History of febrile childhood seizures and non-epileptic seizures are allowed
- Known cardiac abnormality or clinically significant heart disease
- Time-frames are determined relative to the screening visit
- Inability to tolerate the required minimum stimulation amplitude (200 uA) during the initial device training at the baseline visit
- Implanted medical device that uses electricity anywhere in the body
- Pregnant or breast-feeding
- Hospitalization for any reason (current or past 2 weeks)
- Higher than low suicide risk on the Columbia Suicide Severity Rating Scale (C-SSRS)
- Anything that would make participation in the study unsafe or medically unadvisable in the assessment of a study clinician
Where in United States
- Carolina Center for NeurostimulationChapel Hill, United States
About the trial
What the trial wants to find out
The purpose of this research study is to study cranial electrotherapy stimulation (CES) to determine its effects on symptoms of anxiety in people with generalized anxiety disorder (GAD) between the ages of 18 - 21 years of age.
The 2 groups in the trial
- Cranial Electrotherapy Stimulation (CES)Treatment being tested
Alpha-Stim AID ® is an FDA-cleared device for the treatment of anxiety that delivers CES through two earclip electrodes.
Treatment: At-Home Stimulation
- Sham Cranial Electrotherapy Stimulation (CES)Sham treatment, for comparison
The device for sham stimulation is physically identical and delivers a non-therapeutic dose of stimulation to replicate salient features of device usage.
Treatment: At-Home Stimulation
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cranial Electrotherapy Stimulation (CES) for the Treatment of Generalized Anxiety Disorder (GAD) in Young Adults: Double-Blind Sham-Controlled Randomized Clinical Trial
- Record updated
- 18 March 2026